FDA warns Acceleron of possible fines for not posting results from failed trial
In a first for the FDA, the agency on Wednesday said that it sent a notice of noncompliance to Acceleron Pharma for its failure to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
